Oracle and AstraZeneca have entered a collaboration to combine AstraZeneca's scientific expertise with Oracle's AI, cloud, and real-world data capabilities. The partnership aims to accelerate clinical trials by helping clinicians identify eligible patients earlier, improving patient recruitment, and integrating research insights into everyday care. Initial focus areas include oncology, cardiovascular, respiratory, and rare diseases. The companies plan to develop a continuous learning model to enhance study design, safety monitoring, and patient outcomes across multiple diseases and regions.
Oracle shares are trading at USD 129.01 with a slight 0.48% decline, while AstraZeneca is up 0.59% at USD 164.92 on Pluang. Both stocks show strong buy interest, with 90% buy orders for Oracle and 87% for AstraZeneca as of Oct 20, 2026 12:01 WIB.
Oracle's cloud infrastructure revenue more than doubled last quarter, yet its stock price has dropped over 30% this year due to concerns about debt and capital spending. Despite this, Oracle beat revenue and earnings estimates, and raised its fiscal ...
Goldman Sachs upgraded CoreWeave from Neutral to Buy, boosting its stock by 6%. The upgrade comes after a selloff driven by concerns over CoreWeave's heavy debt used to fund its AI-focused data center expansion. Despite debt worries, CoreWeave's oper...
Market volatility surged with the VIX reaching its highest level in four months, driven by inflation fears and geopolitical tensions. AI infrastructure firms like Nebius and CoreWeave face increasing debt default risks, while major tech companies inc...
Bloom Energy shares have risen 157% year-to-date, driven by a major contract supplying fuel cells to Oracle's AI data center project, Project Jupiter. This positions Bloom Energy ahead of competitors in the hydrogen fuel cell sector, as its technolog...
Wednesday's market selloff hit AI stocks unevenly, with companies relying heavily on debt, such as CoreWeave and Nebius, experiencing the steepest declines. Oracle, despite carrying more debt than its peers and having a credit rating just above junk,...
